Release of the economic assessment for Spinraza
All communications and reports regarding supply chain issues caused by COVID-19
The number of patients who were dispensed cilazapril with hydrochlorothiazide and other commonly used anti-hypertensives.
Request for information about the lamotrigine brand change.
Request for information about the discontinuation of phenelzine sulphate.
Request for information and statistics on anti-rejection drugs.
Request for information on the number of people prescribed Utrogestan SA and the cost of this.
Why did the number of declined exceptional circumstances applications for lamotrigine decrease between 5 December 2019 and 18 December 2019?
Request for information about DHB reporting about and claiming of rebates for special foods.
Request for information about the pharmaceutical Tafamidis and its use in the control of amyloidosis.
Information about PHARMAC funding high-cost medicines.
What medicines/ingredients are more expensive (as a result of COVID-19) and by how much have they increased?
NPPA Applications for the last 5 years and the lamotrigine exceptional circumstances applications
The number of complaints received by PHARMAC about funding.
Nationwide Special Authority initiations and renewals by (immunology) indication for adalimumab, etanercept, secukinumab, infliximab, tocilizumab and rituximab, by month from October 2019 to April 2020.
Funding of methylphenidate or similar stimulant medications, for Attention Deficit Hyperactivity Disorder (ADHD).
Special Authority data on pembrolizumab and nivolumab, from Jan 2020 to May 2020.
Information regarding levothyroxine supply in New Zealand.
Ibrutinib funding requests
PHARMAC's budget and expenditure on promoting responsible use of medicines.